Aktuellt
SENASTE
Redeye endorses today’s news that Alzecure will present an abstract in October, which indicates (from pre-clinical research) that its lead candidate from Neurorestore, ACD856, potentially has disease-modifying properties (in addition to memory enhancement). We think that this could be very exciting, and it could increase the value of the treatment significantly if replicated in the clinic. We will return with an interview with Alzecure this week to further discuss the finding.
LÄS MER
